Apalutamide with Triazolam Interaction Details


Brand Names Associated with Apalutamide

  • Apalutamide
  • Erleada®

Brand Names Associated with Triazolam

  • Halcion®
  • Triazolam

Medical Content Editor
Last updated Mar 04, 2024


Curious for more information about this interaction?

Ask our pharmacists directly!

Reach out to us

Interaction Effect

Reduced exposure of substrate


Interaction Summary

Apalutamide is a strong inducer of CYP3A4 and CYP2C19, and weak inducer of CYP2C9. In studies, coadministration of apalutamide with omeprazole (a CYP2C19 substrate) or with midazolam (a CYP3A4 substrate) resulted in decreased apalutamide exposure. Substitution of the medication primarily metabolized by CYP3A4, CYP2C9, or CYP2C19 is recommended during apalutamide therapy. If coadministration is required, evaluate patient for loss of substrate activity[1].


Severity

Moderate


Onset

Unspecified


Evidence

Theoretical


How To Manage Interaction

Apalutamide is a strong inducer of CYP3A4 and CYP2C19, and weak inducer of CYP2C9. Substitution of the medication primarily metabolized by CYP3A4, CYP2C9, or CYP2C19 is recommended during apalutamide therapy. If coadministration is required, evaluate patient for loss of substrate activity[1].


Mechanism Of Interaction

Induction of CYP3A4, CYP2C9, and CYP2C19 metabolism by apalutamide


Literature Reports

A) Coadministration of a single dose of apalutamide with omeprazole, a CYP2C19 substrate, resulted in a 85% decrease in the omeprazole AUC [1].

B) Coadministration of a single dose of apalutamide with midazolam, a CYP3A4 substrate, resulted in a 92% decrease in the midazolam AUC [1].

References

    1 ) Product Information: Erleada(TM) oral tablets, apalutamide oral tablets. Janssen Products, LP (per FDA), Horsham, PA, 2018.

Apalutamide Overview

  • Apalutamide is used to treat certain types of prostate cancer (cancer in men that begins in the prostate [a male reproductive gland]) and has spread to other parts of the body or that has not spread to other parts of the body but has not been helped by other medical treatments. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells.

See More information Regarding Apalutamide

Triazolam Overview

  • Triazolam is used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep). Triazolam is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow sleep.

See More information Regarding Triazolam

Return To Our Drug Interaction Homepage


Feedback, Question Or Comment About This Information?

Ask , our medical editor, directly! He's always more than happy to assist.


Definitions

Severity Categories

Contraindicated

These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.


Major

This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.


Moderate

This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.


Minor

While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.


Onset

Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.

Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.


Evidence

Level of documentation of the interaction.

Established: The interaction is documented and substantiated in peer-reviewed medical literature.

Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.


How To Manage The Interaction

Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.

It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.


Mechanism Of Interaction

The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.


Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.

Where Does Our Information Come From?

Information for our drug interactions is compiled from several drug compendia, including:

The prescribing information for each drug, as published on DailyMED, is also used. 

Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.

The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.